About 3DHEALS Company Directory:

3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members. 

THIS CONTENT IS FOR PREMIUM AND ENTERPRISE MEMBERS ONLY.

Register

Add your company to 3DHEALS Directory:

(Please click the same above buttons for significant updates of your organizational information. Map is updated monthly.)

blank

A.D.A.M.

A.D.A.M. is a biotech company that specializes in on-demand 3D-bioprinting with a primary focus on bone implants.

Headquarters 9 W Broad St Stamford CT 06902 US
  • blank
  • blank
Categories: Bioprinting /Biofabrication, Tissue Engineering
Website: adambioprinting.com/
Facebook: www.facebook.com/ADAM.bioprinting
Twitter: twitter.com/ADAMbioprinting
CEO: Denys Gurak
Links:

Details

A.D.A.M. was founded in 2018 by 3D printing company Kwambio and WeFund Ventures in Ukraine. The initial vision of the company was to create a carshop-like infrastructure where any part of the human body can be treated like a replaceable part. A.D.A.M. team decided to start the development of the project with a focus on bone implants and have developed proprietary 3D printing technology and material composites for the implants. The first prototypes passed pre-clinical trials in wistar rats. Successful results of the trials allowed A.D.A.M. to file the Q-Submission to the FDA. In their response, the FDA confirmed A.D.A.M. biopolymer and bioceramic bone implants’ 510(k) eligibility. Concurrently, the company moved its HQs to the Technology Incubation Program at University of Connecticut.

The company had its first two PCT patents published in 2021. A.D.A.M. is also proud to have been accepted to Elementa Labs, an incubation program of Mount Sinai Innovation Partners.

A.D.A.M. plans to complete the animal studies, required by the FDA, in 2023. Next, the company aims to receive regulatory clearance for bone implants and begin the sales stage in 2024.

Bone implants are just the beginning – in the years to come A.D.A.M. aims to launch R&D of blood vessel, heart valve and bronchial implants.

CBD for pain is gaining traction as a complementary option for everyday discomfort, offering potential anti-inflammatory benefits and calmer sensations without strong sedatives. Results vary, so start with a low dose, choose reputable full- or broad-spectrum products, and monitor changes. Always consult a healthcare professional if you have underlying conditions or take other medications. cbdclub.top